Skip to main content
S&P 5007,718.01-0.34%DOW52,280.68-0.37%NASDAQ26,224.47-1.23%BTC$81,738.00+1.62%ETH$2,366.99+1.62%GOLD$4,036.50-0.37%OIL$100.37-2.34%
Smart Investors Daily
SID Premium
Quest Diagnostics Incorporated logo

NASDAQ · DGX

Quest Diagnostics Incorporated

Healthcare · Medical - Diagnostics & Research

$245.62

Up+$4.88 (+1.99%)

Updated Oct 29, 2026, 3:08 PM

SID Score

6.8/10

Composite research score

Smart Money

47/100

Neutral

Market cap
20.28B
P/E ratio
20.98
Dividend yield
1.61%
52-week range
$173.38 – $249.73
Volume
932.8K
Avg. volume
1.05M

Price performance · DGX

DGX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 28, 2026

DGX closed at $245.62 after 21 trading sessions, up 5.38% for the selected period.

Last close
$245.62
Period change
+5.38%
Period low
$227.06
Period high
$245.62
Daily close
View OHLC price history
DGX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 28, 2026$242.96$249.73$242.34$245.62932.8K
Oct 27, 2026$241.96$243.265$239.59$242.56919.02K
Oct 26, 2026$243.00$244.215$240.98$242.95959.62K
Oct 23, 2026$239.63$244.33$239.63$241.89933.38K
Oct 22, 2026$226.50$246.00$226.22$243.281.69M
Oct 21, 2026$235.34$240.56$223.50$238.931.21M
Oct 20, 2026$236.00$237.29$234.06$237.121.1M
Oct 19, 2026$234.40$235.99$233.82$234.91864.65K
Oct 16, 2026$239.67$240.7499$233.56$235.00799.65K
Oct 15, 2026$235.85$239.17$235.57$239.151M
Oct 14, 2026$231.32$234.97$231.32$233.431.2M
Oct 13, 2026$233.13$234.33$230.23$230.461.01M
Oct 12, 2026$228.66$234.6399$228.66$232.63865.23K
Oct 9, 2026$227.86$232.18$227.86$230.97775.46K
Oct 8, 2026$228.16$231.08$226.36$230.81941.88K
Oct 7, 2026$228.51$229.80$226.81$227.06927.43K
Oct 6, 2026$229.92$232.09$225.78$228.391.78M
Oct 5, 2026$232.93$233.65$229.955$232.221.01M
Oct 2, 2026$230.58$233.48$228.83$233.331.1M
Oct 1, 2026$232.74$233.33$230.47$231.09992.18K
Sep 30, 2026$233.33$236.965$230.84$233.071.09M

Latest DGX news

The latest Smart Investors Daily articles mentioning DGX.

Stock researchCompany · Overview

DGX research

Overview

Company profile and research snapshot.

Company profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$201.60
Implied upside
—
Analysts
24
DGX recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Sep 21, 2026Truist SecuritiesHold—
Sep 8, 2026UBSNeutral—
Jul 28, 2026JP MorganNeutral—
Jul 24, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Quest Diagnostics (DGX) Stock Price Stalls After Strong Q3 Earnings

Quest Diagnostics just posted Q3 2026 results that looked firm on paper while the stock barely flinched. Shares sit at about US$241.89, down 0.6% today and only modestly higher over the past month, even as revenue for the quarter reached roughly US$3.1b and adjusted earnings per share landed near US$3.00. That muted price move appears to reflect investor caution rather than the quality of this report. The market seems to be treating a solid earnings print and raised full year guidance as...

Yahoo · Oct 23, 2026

Quest Diagnostics (DGX) Backs At Home Cervical Cancer Screening

Quest Diagnostics (NYSE:DGX) and Waters Corporation announced a collaboration to expand access to the Onclarity Self-Collection Kit for cervical cancer screening. The partnership focuses on at-home sample collection that can be processed through Quest Diagnostics laboratories using the Onclarity HPV assay. The two companies aim to widen access to clinically appropriate cervical cancer testing for patients who face barriers to in clinic screening. The Onclarity Self-Collection Kit...

Yahoo · Oct 23, 2026

Quest Diagnostics (DGX) Stock Could Be Undervalued Despite Raised Full Year Guidance

Quest Diagnostics has delivered a strong share price run in recent years, and fresh headlines about product expansion and digital health tie-ups keep interest high. With the stock now reflecting years of gains, the open question is whether the business's cash flows are enough to justify where the valuation sits today. Over the past 3 years, Quest Diagnostics has returned 96.2%, which puts a lot of focus on whether its cash generation can continue to support that kind of share price...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By